osteoarthritis

Virpax Pharmaceuticals Inc (NASDAQ: VRPX) reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with osteoarthritis of the knee. Charles River Laboratories International Inc (NYSE: CRL), CRO engaged by Virpax, completed the study...

Ampio Pharmaceuticals Inc (NYSE: AMPE) has reported top-line results from the AP-013 Phase 3 trial evaluating the Company's intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK).  Related Link: Ampio's Phase 2 Study Of...

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee pain (OAK). The Phase 2 trial, a multi-center, double-blind, placebo- and active-controlled study, will assess the efficacy...

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to develop Piclidenoson to treat osteoarthritis in companion animals. Vetbiolix will have the exclusive right to Piclidenoson in...

Galapagos NV (NASDAQ: GLPG) is chopping its pipeline to conserve cash while its business development team pursues a mission to find a “transformative” deal for the company. The company is ditching its Idiopathic pulmonary fibrosis (IPF) molecule ’1205 while...

An expert panel of the U.S. Food and Drug Administration has rejected Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company’s (NYSE: LLY) application to approve their experimental drug for the treatment of osteoarthritis pain, citing safety risks and an inadequate plan to manage them....

Ahead of an advisory committee meeting scheduled for later this week, the FDA released its in-depth review of Pfizer Inc (NYSE: PFE) and Eli Lilly And Co’s (NYSE: LLY) tanezumab, an anti-NGF osteoarthritis drug. What Happened: Potential FDA approval for...

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the stock was trading up 3.7 percent to $5.60. Shares were down 0.46 percent at $5.38...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is about to embark upon a journey with unknown destinations, as investors brace for a trio of reads from the company in the third quarter of 2017. Focus: 3 Phase 2 Reads Of ZYN002 Cantor Fitzgerald said in a note released Monday it remains focused on...